[go: up one dir, main page]

WO2021177247A1 - Séquence activatrice d'absorption de minéraux - Google Patents

Séquence activatrice d'absorption de minéraux Download PDF

Info

Publication number
WO2021177247A1
WO2021177247A1 PCT/JP2021/007771 JP2021007771W WO2021177247A1 WO 2021177247 A1 WO2021177247 A1 WO 2021177247A1 JP 2021007771 W JP2021007771 W JP 2021007771W WO 2021177247 A1 WO2021177247 A1 WO 2021177247A1
Authority
WO
WIPO (PCT)
Prior art keywords
mineral absorption
group
mineral
calcium
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2021/007771
Other languages
English (en)
Japanese (ja)
Inventor
寺尾　啓二
啓太 近本
隆広 古根
吉川　豊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CycloChem Bio Co Ltd
Original Assignee
CycloChem Bio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CycloChem Bio Co Ltd filed Critical CycloChem Bio Co Ltd
Priority to JP2022504361A priority Critical patent/JPWO2021177247A1/ja
Publication of WO2021177247A1 publication Critical patent/WO2021177247A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a mineral absorption promoter. More specifically, the present invention relates to a mineral absorption enhancer containing cyclodextrin (hereinafter, may be simply referred to as CD) as an active ingredient.
  • CD mineral absorption enhancer containing cyclodextrin
  • SCFAs short-chain fatty acids
  • CD is an indigestible oligosaccharide, as a new alternative to this LS.
  • CD is a substance having inclusion properties and is used as various components such as foods and chemicals.
  • a mineral absorption promoter containing a specific cyclic tetrasaccharide and / or a sugar derivative thereof as an active ingredient in Patent Document 1, a sugar that can be contained according to a purpose such as enhancing dispersibility or increasing the amount. It is listed as one of the qualities.
  • ⁇ -CD or ⁇ -CD can be contained as one of the stabilizers.
  • An object of the present invention is to provide a substance having an effect of promoting mineral absorption equal to or higher than that of LS.
  • CD has an effect of promoting absorption of minerals such as calcium, and have completed the present invention.
  • This mineral absorption promoter could also be used as an active ingredient such as a bone mass increasing agent and a bone strength improving agent.
  • the present invention relates to the mineral absorption promoters and the like shown in the following (1) to (4).
  • the mineral absorption promoter of the present invention can be used as it is as a food, a health food, a quasi-drug, a pharmaceutical product, etc., or can be used as an active ingredient such as a bone mass increasing agent or a bone strength improving agent. Can be used for various purposes.
  • test example It is a figure which showed the influence on the improvement of mineral absorption (test example). It is a figure which showed the influence on the bone mass increase (test example). It is a figure which showed the influence on the improvement of bone strength (test example).
  • the "mineral absorption promoter" of the present invention means absorption of minerals into the body of an ingested animal by ingesting it by an animal such as a human, a mouse, a rat, a rabbit, a dog, a cat, a horse, a sheep, a monkey, or a cow.
  • Such a “mineral absorption promoter” of the present invention may be any agent containing CD as an active ingredient. It may be the CD itself, or may be an agent containing other components such as a component capable of assisting mineral absorption such as LS and a component necessary for maintaining the dosage form in addition to the CD.
  • the CD that can be used as the active ingredient of the "mineral absorption promoter" of the present invention may be a CD that can be safely ingested by animals, and may be a commercially available product or an independently prepared CD.
  • Examples of such a CD include ⁇ -CD, ⁇ -CD, ⁇ -CD, maltosyl- ⁇ -CD, maltosyl- ⁇ -CD, maltosyl- ⁇ -CD and the like.
  • One type of these CDs may be used as an active ingredient, or two or more types may be used in combination.
  • Examples of commercially available ⁇ -CD include pure fiber (Kosana Co., Ltd.) and indigestible ⁇ -oligosaccharide (Kosana Co., Ltd.).
  • the mineral whose absorption is promoted by the "mineral absorption promoter" of the present invention may be any mineral useful for the formation of the body of an animal, maintenance of health, etc., and for example, calcium, magnesium, iron, etc. , Copper, zinc and the like, and calcium in particular may be applicable.
  • the "bone mass increasing agent” and “bone strength improving agent” of the present invention are animals ingested by animals such as humans, mice, rats, rabbits, dogs, cats, horses, sheep, monkeys, and cows. An agent that can increase the weight of bones and improve the strength of bones.
  • These "bone mass increasing agent” and “bone strength improving agent” may be any agent containing the "mineral absorption promoting agent” of the present invention as an active ingredient, and the “mineral absorption promoting agent” is the CD itself. May use the CD itself as a “bone mass increasing agent” or a "bone strength improving agent”. Further, in addition to the CD itself, it may be an agent containing other components such as a component useful for increasing bone mass and bone strength, and a component necessary for maintaining a dosage form.
  • the "mineral absorption promoter", "bone mass increasing agent” and “bone strength improving agent” of the present invention may be administered in an amount that is effective in the ingesting animal.
  • the animal to be ingested is a human
  • Example 1 Method for Producing Mineral Absorption Promoter ⁇ -CD was used as it was as a mineral absorption promoter.
  • Table 1 shows the mixing ratio of the experimental feed in each group.
  • the ⁇ -CD or LS content was adjusted to 5.5% in the dry feed. After stirring each powder well, 100 ml of water was added and the mixture was used as an experimental feed. Eight weeks after the start of breeding, rats in each group were fasted overnight and then dissected under isoflurane anesthesia, and the femur and cecum were removed.
  • the contents of the cecum thawed at the stage of bacterial flora analysis are kneaded and homogenized, and the consignment (Technosuruga Lab Co., Ltd.) analyzes the bacterial flora using the T-RFLP method, measures the amount of SCFAs, and analyzes the pH. went.
  • the total amount of SCFAs was calculated by totaling the amounts of lactic acid, succinic acid, acetic acid, propionic acid and butyric acid.
  • the proportion of Lactobacillales in the ⁇ -CD group was higher than that in the NF group or LS group.
  • Analysis of SCFAs levels showed that the ⁇ -CD group significantly increased lactic acid, succinic acid, acetic acid, propionic acid, n-butyric acid and total SCFAs levels compared to the NF group, and lactic acid and succinic acid compared to the LS group. It was confirmed that the amounts of acid, acetic acid, propionic acid, n-butyric acid and total SCFAs increased remarkably.
  • the extracted mineral content was solubilized with 0.01 M hydrochloric acid to prepare an excretory calcium measurement sample and an ingestion calcium measurement sample.
  • the calcium concentration in each sample was measured by metalloassay calcium measurement (OCPC) (Metalogenix Co., Ltd.), and calcium excretion and calcium intake were calculated by the following formulas 1 and 2. The value obtained by subtracting the blank value from these values was taken as the true calcium excretion amount or calcium intake amount.
  • OCPC metalloassay calcium measurement
  • the calcium absorption rate was calculated from each of these true amounts of calcium by the following formulas 3 and 4, and the results are shown in FIG.
  • the group that ingested the experimental diet containing ⁇ -CD ( ⁇ -CD group) was compared with the group that ingested the experimental diet not containing ⁇ -CD or LS (NF group). It was shown that the absorption rate of calcium was significantly improved (p ⁇ 0.05). It was also confirmed that the group that ingested the experimental diet containing ⁇ -CD ( ⁇ -CD group) had a higher calcium absorption rate than the group that ingested the experimental diet containing LS (LS group). ..
  • Bone strength The central part of the femoral bone whose bone mass was measured in 4 and 1) above was measured by the bone strength / skin breaking strength tester TK-252D (Muromachi Kikai Co., Ltd.) at a speed of 3 mm / min and a distance between fulcrums of 1 cm. The bone strength was examined from the measured maximum load after fracture under the conditions of. As a result, as shown in FIG. 3, it was shown that the ⁇ -CD group significantly improved the bone strength as compared with the NF group, and it was confirmed that the improvement in the bone strength was remarkable as compared with the LS group (). p ⁇ 0.05).
  • CD itself has the effect of promoting the absorption of minerals such as calcium equal to or higher than that of LS. Furthermore, it was shown that CD itself has a remarkable effect on increasing bone mass and bone strength.
  • the neral absorption promoter of the present invention can be used as it is as a food, a health food, a quasi-drug, a pharmaceutical product, etc., or can be used as an active ingredient such as a bone mass increasing agent or a bone strength improving agent. Can be used for various purposes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Polymers & Plastics (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Fourniture d'une substance ayant un effet d'amélioration de l'absorption de minéraux égale ou supérieure à celle de LS.　L'invention concerne une séquence activatrice d'absorption de minéraux contenant de la cyclodextrine en tant que principe actif, en tant que substance ayant un effet d'amélioration de l'absorption de minéraux égale ou supérieure à celle de LS. L'invention concerne également des agents augmentant la masse osseuse, des agents améliorant la résistance osseuse, etc., ayant ladite séquence activatrice d'absorption de minéraux en tant que principe actif.
PCT/JP2021/007771 2020-03-02 2021-03-01 Séquence activatrice d'absorption de minéraux Ceased WO2021177247A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022504361A JPWO2021177247A1 (fr) 2020-03-02 2021-03-01

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020035184 2020-03-02
JP2020-035184 2020-03-02

Publications (1)

Publication Number Publication Date
WO2021177247A1 true WO2021177247A1 (fr) 2021-09-10

Family

ID=77614261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/007771 Ceased WO2021177247A1 (fr) 2020-03-02 2021-03-01 Séquence activatrice d'absorption de minéraux

Country Status (2)

Country Link
JP (1) JPWO2021177247A1 (fr)
WO (1) WO2021177247A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0833463A (ja) * 1994-07-25 1996-02-06 Micro Arujie Corp Kk カルシウムを主成分とする健康食品
JP2008280322A (ja) * 2007-05-11 2008-11-20 Bhn Kk 骨強化剤
KR20090040751A (ko) * 2007-10-22 2009-04-27 경포대영어조합법인 모자반 추출물을 주요성분으로 함유하는 칼슘흡수 보조제및 이의 제조방법
WO2009146490A1 (fr) * 2008-06-03 2009-12-10 John Ray Biffin Méthode renforçant la densité osseuse et/ou réduisant les défauts ostéochondraux chez l'animal, et composition comportant de la vitamine k
JP2010509320A (ja) * 2006-11-06 2010-03-25 ハンミ ファーム． シーオー．， エルティーディー． ビタミンｄ又はその誘導体の固体分散体とビスホスホネートとを含む、骨粗鬆症の予防又は治療用複合製剤
JP2017048154A (ja) * 2015-09-03 2017-03-09 一般社団法人 Ｕｎｉｃａｌ 易吸収性カルシウム液、易吸収性カルシウム粉末、易吸収性カルシウム含有飲料
WO2018016100A1 (fr) * 2016-07-22 2018-01-25 一般社団法人 Ｕｎｉｃａｌ Procédé de production de granulés de sel de calcium et desdits granulés

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0833463A (ja) * 1994-07-25 1996-02-06 Micro Arujie Corp Kk カルシウムを主成分とする健康食品
JP2010509320A (ja) * 2006-11-06 2010-03-25 ハンミ ファーム． シーオー．， エルティーディー． ビタミンｄ又はその誘導体の固体分散体とビスホスホネートとを含む、骨粗鬆症の予防又は治療用複合製剤
JP2008280322A (ja) * 2007-05-11 2008-11-20 Bhn Kk 骨強化剤
KR20090040751A (ko) * 2007-10-22 2009-04-27 경포대영어조합법인 모자반 추출물을 주요성분으로 함유하는 칼슘흡수 보조제및 이의 제조방법
WO2009146490A1 (fr) * 2008-06-03 2009-12-10 John Ray Biffin Méthode renforçant la densité osseuse et/ou réduisant les défauts ostéochondraux chez l'animal, et composition comportant de la vitamine k
JP2017048154A (ja) * 2015-09-03 2017-03-09 一般社団法人 Ｕｎｉｃａｌ 易吸収性カルシウム液、易吸収性カルシウム粉末、易吸収性カルシウム含有飲料
WO2018016100A1 (fr) * 2016-07-22 2018-01-25 一般社団法人 Ｕｎｉｃａｌ Procédé de production de granulés de sel de calcium et desdits granulés

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHIKAMOTO KEITA ET AL.: "Calcium absorption promoting effect by indigestiblea-cyclodextrin intake", APPLIED GLYCOSCINECE 2020 CONFERENCE 69TH, vol. 10, no. 4, 20 November 2020 (2020-11-20) *

Also Published As

Publication number Publication date
JPWO2021177247A1 (fr) 2021-09-10

Similar Documents

Publication Publication Date Title
AU2004294986B2 (en) Method to reduce stool odor of companion animals
Kozlowska et al. 2. Beneficial Aspects of Inulin Supplementation as a Fructooligosaccharide Prebiotic in Monogastric Animal Nutrition-A Review
Quarterman et al. The influence of high dietary calcium and phosphate on lead uptake and release
PL193320B1 (pl) Zastosowanie mieszaniny zawierającej gwajakol, tymol, engenol, kapsaicynę, taninę i krezol
Garcia et al. Dietary supplements of vitamins E, C, and β-carotene to reduce oxidative stress in horses: an overview
JP7457713B2 (ja) 軟骨再生促進用組成物
JP2012016293A (ja) 家禽用飼料
MXPA05012050A (es) Complemento dietetico y metodo para el tratamiento y prevencion de ulceras del tracto digestivo en equinos y otros animales.
US11116809B2 (en) Biopolymer compositions for the treatment and prevention of liver disease
Maronpot et al. Evaluation of 90-day oral rat toxicity studies on the food additive, gum ghatti
AU2004296213B2 (en) Anti-diarrhea composition containing glutamine
Masanetz et al. Effects of inulin and lactulose on the intestinal morphology of calves
WO2021177247A1 (fr) Séquence activatrice d'absorption de minéraux
Lepczyński et al. Inulin-type fructans trigger changes in iron concentration and activity of bone metabolism biomarkers in blood plasma of growing pigs.
Samolinska et al. Effects of inulin extracts and inulin-containing plants on haematobiochemical responses, plasma mineral concentrations, and carcass traits in growing-finishing pigs
JP4290223B2 (ja) 下痢止め剤および抗潰瘍剤として使用される、ペクチンとリン脂質とを含有する医薬組成物
JP5393450B2 (ja) 腸管病原体に対する凝集剤として好適なトリ−およびテトラ−オリゴ糖
CA3035290A1 (fr) Utilisation d'oligosaccharides de lait humain pour l'engraissement de veaux
Salmon et al. The effects of dietary fructo-oligosaccharide addition on boar taint compounds and performance in heavy slaughter weight boars and gilts
DK1993375T3 (en) Hitherto UNKNOWN USE OF NUTRACEUTIC COMPOSITIONS IN ANIMAL FEED.
Kerr et al. Soluble corn fiber, resistant corn starch, and protected butyrate effects on performance, gastrointestinal volatile fatty acids, and apparent total-tract digestibility of calcium and phosphorus in nursery pigs
Araújo et al. Effect of odontoplasty on apparent digestibility and consumption time of diet for equines
IVANOVA et al. EFFECT OF DIHYDROQUERCETIN ON PERFORMANCE, BACK FAT THICKNESS AND BLOOD BIOCHEMICAL INDICES IN FATTENING PIGS.
JP2008237193A (ja) 鶏の腸内ｐＨ制御方法と養鶏用飼料
JPWO2006120974A1 (ja) 軟骨代謝異常疾患改善用健康食品及び医薬品組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21764026

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022504361

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21764026

Country of ref document: EP

Kind code of ref document: A1